Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial (Nature Medicine, (2026), 10.1038/s41591-026-04455-x)

Wermke M, Ochsenreither S, Jaeger D, Becker H, Bleckmann A, Bozorgmehr F, Chatterjee M, Groepper S, Haenel M, Hecker JS, Häring MF, Heudobler D, Hilf N, Hofmann M, Hutt M, Mayer-Mokler A, Missel S, Ruh M, Schuster H, Veremchuk O, Kleemiss M, Knop S, Laban S, Sebastian M, Spörl S, Britten CM, Reinhardt C (2026)

Publication Type: Journal article, Erratum

Publication year: 2026

Journal

DOI: 10.1038/s41591-026-04519-y

Abstract

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-026-04455-x, published online 31 May 2026. In the version of the article initially published, in the “Phase 1a dose escalation” column in Fig. 2, the fifth dose was listed as “0.054 mg” but should have been “0.54 mg”. This correction has been made to the HTML and PDF versions of the article.

Authors with CRIS profile

Involved external institutions

Technische Universität Dresden Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE) Deutsches Krebsforschungszentrum (DKFZ) Germany (DE) Universitätsklinikum Freiburg Germany (DE) Universitätsklinikum Münster Germany (DE) Universitätsklinikum Würzburg Germany (DE) Marien Hospital Düsseldorf Germany (DE) Klinikum Chemnitz Germany (DE) Klinikum rechts der Isar Germany (DE) Universitätsklinikum Tübingen Germany (DE) Universitätsklinikum Regensburg Germany (DE) Immatics Biotechnologies GmbH Germany (DE) Universitätsklinikum Bonn Germany (DE) Klinikum Nürnberg Germany (DE) Universitätsklinikum Ulm Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) Germany (DE)

How to cite

APA:

Wermke, M., Ochsenreither, S., Jaeger, D., Becker, H., Bleckmann, A., Bozorgmehr, F.,... Reinhardt, C. (2026). Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial (Nature Medicine, (2026), 10.1038/s41591-026-04455-x). Nature Medicine. https://doi.org/10.1038/s41591-026-04519-y

MLA:

Wermke, Martin, et al. "Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial (Nature Medicine, (2026), 10.1038/s41591-026-04455-x)." Nature Medicine (2026).

BibTeX: Download